Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here’s Why

Eli Lilly and Company (NYSE:LLY)’s share price traded down 1.3% during trading on Tuesday. The company traded as low as $1,158.41 and last traded at $1,167.0070. 1,836,608 shares traded hands during mid-day trading, a decline of 38% from the average session volume of 2,952,272 shares. The stock had previously closed at $1,182.62.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Retatrutide is viewed as a potentially major next-generation obesity treatment, with the possibility of becoming a growth driver larger than Zepbound if clinical results and regulatory progress remain favorable. Eli Lilly Reports Earnings on Oct. 29
• Positive Sentiment: Prelude Therapeutics is collaborating with Lilly to test the experimental cancer drug PRT13722 alongside Verzenio and Inluriyo in HR-positive, HER2-negative breast cancer. Patient enrollment is expected to begin in the fourth quarter of 2026, offering Lilly another opportunity to expand beyond its cardiometabolic franchise. Prelude Announces Clinical Trial Collaboration with Lilly
• Positive Sentiment: Analyst earnings estimates remain supportive. Erste Group raised its forecasts to $36.55 per share for fiscal 2026 and $47.30 for fiscal 2027, above the current consensus estimate of $36.19 for 2026. Eli Lilly analyst estimates
• Positive Sentiment: Royal Bank of Canada reaffirmed an Outperform rating with a $1,500 price target, citing continued strength in diabetes and weight-loss drug sales and the potential for a higher revenue outlook. Royal Bank of Canada reiterates Outperform rating
• Neutral Sentiment: Lilly’s Taltz-Zepbound combination produced broader biomarker changes, greater skin clearance and weight loss in a Phase 3b psoriasis study, but the commercial significance of the results remains to be established. Lilly reports Phase IIIb data on Taltz and Zepbound
• Negative Sentiment: Investors remain sensitive to valuation: Lilly trades at a premium multiple after substantial gains, increasing the risk of profit-taking or disappointment if earnings guidance and pipeline updates do not exceed elevated expectations. A retatrutide combination also generated more weight loss than Zepbound but had materially higher discontinuation rates, highlighting execution and tolerability risks. Retatrutide combination study results

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Wells Fargo & Company upped their price objective on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. TD Cowen reaffirmed a “buy” rating and set a $1,250.00 price target on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. Cantor Fitzgerald increased their price objective on shares of Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the company an “overweight” rating in a report on Thursday, October 8th. UBS Group set a $1,376.00 target price on shares of Eli Lilly and Company in a report on Friday, August 7th. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, October 1st. One research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $1,313.43.

Eli Lilly and Company Stock Down 1.3%

The company has a market cap of $1.10 trillion, a P/E ratio of 39.16, a P/E/G ratio of 1.47 and a beta of 0.46. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The business’s 50 day moving average is $1,175.57 and its 200 day moving average is $1,100.31.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. During the same period last year, the business earned $6.31 EPS. The company’s revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 36.19 earnings per share for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In other news, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 13,500 shares of company stock worth $15,958,170. Company insiders own 0.14% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and Company

Several institutional investors and hedge funds have recently modified their holdings of LLY. Cascade Investment Group Inc. boosted its stake in Eli Lilly and Company by 2.4% during the 3rd quarter. Cascade Investment Group Inc. now owns 426 shares of the company’s stock valued at $493,000 after acquiring an additional 10 shares during the last quarter. First County Bank CT increased its holdings in shares of Eli Lilly and Company by 5.9% in the 3rd quarter. First County Bank CT now owns 1,397 shares of the company’s stock valued at $1,616,000 after acquiring an additional 78 shares during the last quarter. Ring Mountain Capital LLC increased its holdings in shares of Eli Lilly and Company by 5.8% in the 3rd quarter. Ring Mountain Capital LLC now owns 349 shares of the company’s stock valued at $404,000 after acquiring an additional 19 shares during the last quarter. Steel Grove Capital Advisors LLC raised its position in shares of Eli Lilly and Company by 150.6% during the 3rd quarter. Steel Grove Capital Advisors LLC now owns 1,526 shares of the company’s stock valued at $1,765,000 after acquiring an additional 917 shares in the last quarter. Finally, Sax Wealth Advisors LLC lifted its stake in Eli Lilly and Company by 450.0% during the third quarter. Sax Wealth Advisors LLC now owns 8,410 shares of the company’s stock worth $9,731,000 after purchasing an additional 6,881 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.